Tempus AI, Inc. a pioneering company in the fields of artificial intelligence (AI) and precision medicine, has revealed its plan to partner strategically with Daiichi Sankyo to accelerate biomarker discovery and improve clinical differentiation in an antibody-drug conjugate (ADC) oncology program. Such a partnership is the industry’s way of showing that the entire pharmaceutical world is trying to capitalize on the enormous potential that AI holds for drug development. This is particularly true for cancer treatment where precision and patient-specific data are the main factors in determining patient outcomes.
As part of this collaboration, Daiichi Sankyo will utilize Tempus’s proprietary AI technologies, including its multimodal foundation model, PRISM2. PRISM2 combines pathology images and clinical information to provide more profound diagnostic and predictive insights, allowing for more informed decision-making throughout the drug development process.
The project will merge Daiichi Sankyo’s clinical trial data and preclinical research data with Tempus’ large real-world oncology dataset. Combining these data resources is expected to open up new possibilities in biomarker discovery. Also, it will help in implementing accurate patient stratification strategies which is a crucial factor in not only raising trial success rates but also the effectiveness of treatments. The collaboration will greatly focus on creating AI-based proof-of-concept models aimed at improving patient selection for a new ADC therapy. These models will be used on Tempus’ large cancer patient database to create detailed response maps which will not only allow researchers to better grasp treatment responses but also lead to identifying ideal patient cohorts. Besides, the models will aid in benchmarking the potential control arms which will, in turn, enhance the design and running of future clinical trials.
Also Read: Unchained Labs Unveils Stuntman – An AI-Driven Automation Platform Set to Transform Scientific Workflows
“Our collaboration with Daiichi Sankyo signals a new chapter in how multimodal AI and real-world data can be applied to advance the development of ADCs,” said Ryan Fukushima, CEO of Data and Apps at Tempus. “Our multimodal foundation models seek to radically accelerate and improve our ability to uncover unmet patient needs and identify patients most likely to benefit from novel therapies. Applying AI in clinical development isn’t just about efficiency anymore, leading companies like Daiichi Sankyo are using these models to enhance the design of more targeted, impactful clinical trials.”
This partnership highlights the rise of AI-based systems in the drug development process. This change will probably be most visible in cancer treatment, where the choice of patient group usually has a very strong impact on the success of a clinical trial. By making use of very large datasets and deep learning methods, Tempus is successfully asserting its leadership in the field of precision medicine. As a technology company aiming at making precision medicine the norm, Tempus uses AI to great effect. Since the company has access to one of the largest global repositories of multimodal healthcare data, it is able to offer AI-based tools through which doctors can not only deliver personalized treatment but also assist pharmaceutical companies in the whole cycle of finding, developing, and marketing new drugs.
